adalimumab vs infliximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody (fully human IgG1)
Partial signal

NCT00055497 · Phase 3 · completed

Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.

Next expected readout: June 2027 · NCT06045754 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)

Result source: NCT02499783

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00094458 · Phase 3 · completed

This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).

Next expected readout: November 2026 · NCT05906576 (registry estimate)

Reported efficacy

Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)

Result source: NCT00094458

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabinfliximab
Clinical remission (induction)37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
Endoscopic response (induction)—Trial running · NCT05040464—Not posted · NCT00004941
Clinical remission (maintenance)47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
Endoscopic response (maintenance)—Trial running · NCT05040464—Not posted · NCT00004941

Clinical remission (induction)

adalimumab
37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
infliximab
47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458

Endoscopic response (induction)

adalimumab
—Trial running · NCT05040464
infliximab
—Not posted · NCT00004941

Clinical remission (maintenance)

adalimumab
47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
infliximab
66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458

Endoscopic response (maintenance)

adalimumab
—Trial running · NCT05040464
infliximab
—Not posted · NCT00004941
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. adalimumab: 9 of 9 rows · infliximab: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
infliximab
Rows use multiple source trials
CDAI
responder rate · % of participants
Induction
67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mga,b
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
69.2% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wkc,a,b
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 1 more dose
55.6% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
CDAI
absolute change · score
No placebo or comparator arm
-173.55 score @ 36wkd
NCT00686374 · Phase 3 · monotherapy
139 score @ 36wkd
NCT00805766 · Phase 3 · monotherapy
Clinical Remission
responder rate · % of participants
29.7% (n=64) vs 4.6% (n=65) placebo*e
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Subjects as posted
60.4% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wkc,e
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 1 more dose
49.7% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
Clinical Remission
responder rate · % of participants
No placebo or comparator arm
80% (n=65) @ 36wk*d
NCT00686374 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
1 other source trial
39.3% (n=28) @ 36wk80 mg
NCT01958827 · Phase 3 · monotherapy
59.3% (n=39) @ 36wkd
NCT00805766 · Phase 3 · monotherapy
PCDAI
absolute change · score
No placebo or comparator arm
-46.25 score @ 384wkf,g
NCT00686374 · Phase 3 · monotherapy
-28.33 score @ 54wkf,g
NCT01580670 · Phase 3 · monotherapy
Dropout rate
—40 mg every other weekh
NCT00055497 · Phase 3
show 34 more results
15.8%40 mg every other week
NCT00055497 · Phase 3
11.1%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
40.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
48.5%
NCT00195715 · Phase 3
16.9%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.4%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.8%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
6.8%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
21.4%
NCT02185014 · Phase 3 · monotherapy
61%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
34.4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
35.7%80 mg
NCT01958827 · Phase 3 · monotherapy
16.4%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
36%
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
26.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
28.4%Infliximab + Azathioprinei
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
34.3%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
0%
NCT01580670 · Phase 3 · monotherapy
13.3%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weekh
NCT00055497 · Phase 3
show 34 more results
5.3%40 mg every other week
NCT00055497 · Phase 3
5.6%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
12.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
15.7%
NCT00195715 · Phase 3
6%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.5%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3.9%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
2.4%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
7.1%
NCT02185014 · Phase 3 · monotherapy
8%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
21.9%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
10.7%80 mg
NCT01958827 · Phase 3 · monotherapy
10.9%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
—
NCT02148718 · Phase 4 · registry result, not featured evidence
20%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
20%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
16.6%Infliximab + Azathioprinei
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
11.8%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—
NCT01580670 · Phase 3 · monotherapy
2.2%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
5.3%40 mg every other weekh
NCT00055497 · Phase 3
show 34 more results
—40 mg every other week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
0%40 mg every week
NCT00055497 · Phase 3
16.7%40 mg
NCT00055497 · Phase 3
2%160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
38.1%
NCT00195715 · Phase 3
—40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.8%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.5%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.9%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.6%Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
6.4%Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
10.7%
NCT02185014 · Phase 3 · monotherapy
48%
NCT00686374 · Phase 3 · monotherapy
23.7%40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20%20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
40.6%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
28.6%80 mg
NCT01958827 · Phase 3 · monotherapy
—40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
2.3%
NCT02148718 · Phase 4 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
7.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
14.3%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Infliximab + Azathioprinei
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
—Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14%W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
16%W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
1.9%W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.5%W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14.3%
NCT01580670 · Phase 3 · monotherapy
—
NCT00805766 · Phase 3 · monotherapy
9.1%
NCT00688636 · Phase 4 · registry result, not featured evidence
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weekh
nasopharyngitis 26.3% (placebo 38.9%)
crohn's disease aggravated 21.1% (placebo 27.8%)
sinusitis 21.1% (placebo 5.6%)
NCT00055497 · Phase 3
show 28 more results
40 mg every week
crohn's disease aggravated 11.1% (placebo 27.8%)
dizziness (excl vertigo) 11.1% (placebo 5.6%)
nasopharyngitis 11.1% (placebo 38.9%)
NCT00055497 · Phase 3
40 mg
crohn's disease aggravated 17.6% (placebo 27.8%)
nasopharyngitis 16.7% (placebo 38.9%)
headache 14% (placebo 11.1%)
NCT00055497 · Phase 3
160/80 mg
white blood cell count decreased 5.9% (placebo 1%)
cough 4.9% (placebo 0%)
dizziness 3.9% (placebo 0%)
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 39.8%
nasopharyngitis 26.1%
arthralgia 24.7%
NCT00195715 · Phase 3
40 mg every other week or every week
headache 18.9%
nasopharyngitis 14.4%
arthralgia 7.6%
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 23.4% (placebo 29.2%)
headache 14.1% (placebo 9.2%)
nasopharyngitis 14.1% (placebo 12.3%)
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 6.2%
headache 5.5%
crohn's disease 4.5%
NCT02065570 · Phase 3 · monotherapy
headache 8.7%
arthralgia 7.8%
nausea 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 14.7%
nasopharyngitis 13.8%
headache 8.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 13.8%
nasopharyngitis 9.2%
headache 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 11.9%
arthralgia 7.1%
nausea 6%
NCT02185014 · Phase 3 · monotherapy
viral upper respiratory tract infection 39%
headache 37%
upper respiratory tract infection 31%
NCT00686374 · Phase 3 · monotherapy
40 mg or 20 mg every other week
headache 17.2%
crohn's disease 11.8%
nausea 10.8%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20 mg or 10 mg every other week
headache 21.1%
crohn's disease 15.8%
nasopharyngitis 11.6%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
40 mg Eow
nasopharyngitis 56% (placebo 12%)
rhinorrhoea 16% (placebo 0%)
adverse drug reaction 12% (placebo 4%)
NCT00445432 · Phase 2/3 · monotherapy
40 mg Eow
nasopharyngitis 71.9% (placebo 12%)
adverse drug reaction 18.8% (placebo 4%)
iron deficiency anaemia 18.8% (placebo 0%)
NCT00445432 · Phase 2/3 · monotherapy
160 mg/80 mg + 40/40 mg
adverse drug reaction 11.1% (placebo 4.3%)
application site swelling 11.1% (placebo 0%)
blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
160 mg/80 mg
headache 9.1% (placebo 4.3%)
upper respiratory tract infection 9.1% (placebo 4.3%)
abdominal distension 6.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80/40 mg + 40/40 mg
headache 16.7% (placebo 4.3%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 4.3%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg/40 mg
injection site reaction 8.8% (placebo 8.7%)
malaise 8.8% (placebo 0%)
rhinorrhoea 8.8% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg
nasopharyngitis 46.4%
rash 14.3%
headache 10.7%
NCT01958827 · Phase 3 · monotherapy
40 mg every other week
crohn's disease 16.1%
abdominal pain 7.6%
injection site reaction 7.6%
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
arthralgia 18.2%
crohn's disease 16.4%
nasopharyngitis 10.9%
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
vomiting 7%
abdominal mass 5.8%
arthralgia 4.7%
NCT02148718 · Phase 4 · registry result, not featured evidence
Low Induction Dose
leukopenia 20%
pyrexia 13.3%
arthralgia 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Low Induction Dose
leukopenia 15.4%
animal bite 7.7%
aphthous stomatitis 7.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
alanine aminotransferase increased 13.3%
aspartate aminotransferase increased 13.3%
abdominal pain 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
mycobacterium tuberculosis complex test positive 14.3%
aspartate aminotransferase increased 7.1%
asthenia 7.1%
NCT02015793 · Phase 2 · registry result, not featured evidence
i
nausea 21.8%
abdominal pain 13.4%
fatigue 13.4%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 6 more results
abdominal pain 20.9%
nausea 16.6%
arthralgia 14.1%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
abdominal pain 9.3%
nasopharyngitis 8.3%
crohn's disease 5.6%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
abdominal pain 11.3%
nausea 11.3%
vomiting 11.3%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
double stranded dna antibody positive 50%
gastroenteritis 21.4%
headache 21.4%
NCT01580670 · Phase 3 · monotherapy
infusion reaction 18.2% (placebo 7.7%)
abcess 9.1% (placebo 7.7%)
bronchitis 9.1% (placebo 0%)
NCT00688636 · Phase 4 · registry result, not featured evidence
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation context differs: prior_therapy differs (experienced versus none recorded).
  2. bAssessment timepoints differ: 4 weeks versus 10 weeks.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gAssessment timepoints differ: 384 weeks versus 54 weeks.
  8. hPopulation comparability has not been reviewed for 24 of these studies.
  9. iPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

CR-100 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
CR-70 68.4% (n=19) vs 44.4% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
show 11 more results
94.4% (n=18) vs 44.4% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
60.3% (n=204) vs 44.4% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 123 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
53.9% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
94.7% (n=19) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 18 Participants as posted
94.4% (n=18) vs 83.3% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
70.6% (n=204) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 144 Participants as posted
78.9% (n=19) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
88.9% (n=18) vs 72.2% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 16 Participants as posted
72.1% (n=204) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 147 Participants as posted
IBDQ 43.4 vs 29.9 placebo score @ 24wk40 mg every other week
absolute change · score
Maintenance
NCT00055497 · Phase 3
show 6 more results
51.9 vs 29.9 placebo score @ 24wk40 mg every week
NCT00055497 · Phase 3
33.9 vs 29.9 placebo score @ 24wk40 mg every other week
NCT00055497 · Phase 3
45.7 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
45.2 vs 24.7 placebo score @ 56wk40 mg every week
NCT00055497 · Phase 3
36 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
27.8 vs 1.8 placebo score @ 52wk40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
IBDQ Remission 40.2% (n=102) vs 20.4% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response 100 85.7% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Response 70 91.2% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Corticosteroid-free Clinical Remission 50% (n=16) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
responder rate · % of participants
No placebo or comparator arm
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
56.3% (n=16) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
63.1% (n=103) @ 156wk
NCT00195715 · Phase 3
48% (n=100) @ 12wk
NCT02065570 · Phase 3 · monotherapy
52.9% (n=155) @ 12wk
NCT02065570 · Phase 3 · monotherapy
Steroid-free Clinical Response 100 74.8% (n=103) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Fistula Remission 55.8% (n=43) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Remission 52.1% (n=945) @ 20wk40 mg every other week or every week
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 492 Participants as posted
show 1 more result
15.6% (n=32) @ 52wk*40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy · converted to % from 5 Participants as posted
HBI 69.6% (n=945) @ 20wk40 mg every other week or every week
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 658 Participants as posted
Fistula 35.8% (n=148) @ 20wk40 mg every other week or every week
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 53 Participants as posted

+ 55 further endpoints in the CSV export.

infliximab

Corticosteroid-free Clinical Remission 44.4% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
responder rate · % of participants
Maintenance
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
56.8% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
60.8% (n=97) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
72.2% (n=108) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Mucosal Healing 30.1% (n=93) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
responder rate · % of participants
Maintenance
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
43.9% (n=107) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
CDAI 55% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
62.7% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
CDAI 54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
responder rate · % of participants
Maintenance
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
62.1% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
76.3% (n=97) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
76.9% (n=108) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
74.2% (n=97) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
77.8% (n=108) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
72.2% (n=97) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
78.7% (n=108) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
IBDQ Total 27.7 vs 20.1 Azathioprine + Placebo score @ 2wk
absolute change · score
Induction
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 5 more results
31.4 vs 20.1 Azathioprine + Placebo score @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
34.8 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
39.9 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
37.8 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
42.4 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
IBDQ Total 39.9 vs 30.3 Azathioprine + Placebo score @ 18wk
absolute change · score
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
43.7 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
IBDQ Total 39.9 vs 31.4 Azathioprine + Placebo score @ 26wk
absolute change · score
Maintenance
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
45.2 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Average Corticosteroid Use mg Per 21.2 vs 22.92 Azathioprine + Placebo per day @ 2wk
absolute value · per day
Induction
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 5 more results
22.75 vs 22.92 Azathioprine + Placebo per day @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
17.68 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
18.26 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.68 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
15.01 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Average Corticosteroid Use mg Per 13.23 vs 13.49 Azathioprine + Placebo per day @ 18wk
absolute value · per day
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
11.64 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Average Corticosteroid Use mg Per 10.96 vs 11.57 Azathioprine + Placebo per day @ 26wk
absolute value · per day
Maintenance
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
9.35 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
PCDAI 78.6% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
100% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI 85.7% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy

+ 7 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Partial signal

NCT00385736 · Phase 3 · completed

Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.

Next expected readout: September 2027 · NCT06257875 (registry estimate)

Reported efficacy

Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)

Result source: NCT00408629

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody (chimeric IgG1)
Weak signal

NCT01585155 · Phase 3 · completed

No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.

Next expected readout: December 2026 · NCT06839820 (registry estimate)

Reported efficacy

Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%

Result source: NCT01585155

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabinfliximab
Clinical remission (induction)10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
—Trial running · NCT06614387
Clinical remission (maintenance)20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
—Trial running · NCT06614387
Clinical response (induction)50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Trial running · NCT06614387
Endoscopic improvement (induction)44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Trial running · NCT06614387
Corticosteroid-free remission (maintenance)13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
—Trial running · NCT06614387

Clinical remission (induction)

adalimumab
10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
infliximab
—Trial running · NCT06614387

Clinical remission (maintenance)

adalimumab
20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
infliximab
—Trial running · NCT06614387

Clinical response (induction)

adalimumab
50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
infliximab
—Trial running · NCT06614387

Endoscopic improvement (induction)

adalimumab
44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
infliximab
—Trial running · NCT06614387

Corticosteroid-free remission (maintenance)

adalimumab
13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
infliximab
—Trial running · NCT06614387
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. adalimumab: 5 of 5 rows · infliximab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumabinfliximab
PUCAI Remission
responder rate · % of participants
No placebo or comparator arm
40.7% (n=59) @ 288wk*a,b
NCT02632175 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
18.2% (n=22) @ 54wk*5 mg/kg every 12 weeksc,a,b
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 4 Participants as posted
show 1 more dose
38.1% (n=21) @ 54wk*5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 8 Participants as posted
Dropout rate
6.9%160/80/40d
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
9.2%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.6%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52.5%
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
10.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.4%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
34.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%d
NCT01585155 · Phase 3 · monotherapy
show 3 more results
47.8%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.2%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
3.1%160/80/40d
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
4.6%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
14.3%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
4.8%d
NCT01585155 · Phase 3 · monotherapy
show 3 more results
26.1%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.6%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
4%160/80/40d
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
3.8%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
12.1%Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.1%
NCT02632175 · Phase 3 · monotherapy
7.8%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
5.6%open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.6%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
13.9%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.2%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.8%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
5%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.6%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.8%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
9.9%Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
11.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.1%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.5%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.3%d
NCT01585155 · Phase 3 · monotherapy
show 3 more results
21.7%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.2%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
160/80/40d
colitis ulcerative 4% (placebo 3.6%)
fatigue 4% (placebo 2.2%)
headache 3.1% (placebo 7.2%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 17 more results
80/40
headache 6.9% (placebo 7.2%)
colitis ulcerative 5.4% (placebo 3.6%)
nasopharyngitis 4.6% (placebo 1.8%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 17.5% (placebo 10.4%)
colitis ulcerative 16.3% (placebo 22.3%)
headache 8.6% (placebo 14.2%)
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 33.9%
upper respiratory tract infection 27.1%
nasopharyngitis 22%
NCT02632175 · Phase 3 · monotherapy
high dose
headache 9.8% (placebo 16.7%)
anaemia 5.9% (placebo 8.3%)
nausea 5.9% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
open-label high dose
headache 22.2% (placebo 16.7%)
abdominal pain 11.1% (placebo 8.3%)
oropharyngeal pain 11.1% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 12.5% (placebo 16.7%)
colitis ulcerative 6.3% (placebo 16.7%)
nasopharyngitis 6.3% (placebo 8.3%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
high dose
colitis ulcerative 11.1% (placebo 16.7%)
nasopharyngitis 11.1% (placebo 8.3%)
upper respiratory tract infection 11.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 18.2% (placebo 16.7%)
c-reactive protein increased 9.1% (placebo 0%)
colitis ulcerative 9.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 8.4%
nasopharyngitis 5.1%
arthralgia 3.1%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 6.1%
colitis ulcerative 5.3%
nasopharyngitis 4.2%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 13.4%
nasopharyngitis 13.1%
arthralgia 6.6%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 17.4%
nasopharyngitis 13.6%
arthralgia 6.7%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 15.2%
nasopharyngitis 7.3%
upper respiratory tract infection 6%
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
40 mg EOW/EW
colitis ulcerative 30.4%
viral upper respiratory tract infection 19.4%
arthralgia 10.5%
NCT00573794 · Phase 3 · monotherapy
160 mg/80 mg
nasopharyngitis 33.3% (placebo 21.9%)
iron deficiency anaemia 8.9% (placebo 7.3%)
headache 7.8% (placebo 6.3%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
80 mg/40 mg
nasopharyngitis 21.8% (placebo 21.9%)
injection site reaction 8% (placebo 2.1%)
dental caries 6.9% (placebo 5.2%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 13.2%
headache 13%
nasopharyngitis 8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
d
double stranded dna antibody positive 57.1%
nasopharyngitis 33.3%
acne 9.5%
NCT01585155 · Phase 3 · monotherapy
show 3 more results
5 mg/kg every 12 weeks
colitis ulcerative 65.2%
upper respiratory tract infection 26.1%
pain 17.4%
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5 mg/kg every 8 weeks
colitis ulcerative 31.8%
upper respiratory tract infection 31.8%
fever 27.3%
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bAssessment timepoints differ: 288 weeks versus 54 weeks.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 6 more results
10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10% (n=130) vs 9.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.5% (n=130) vs 9.2% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.5% (n=248) vs 9.3% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 50% (n=90) vs 35.4% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
42.5% (n=87) vs 35.4% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
54.6% (n=130) vs 44.6% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.5% (n=130) vs 44.6% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50.4% (n=248) vs 34.6% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Rectal Bleeding Subscore 0 1 77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Remission 20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 14 more results
17.8% (n=90) vs 8.3% (n=96) placebo @ 32wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.2% (n=87) vs 8.3% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.3% (n=248) vs 8.5% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
29% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.3% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.5% (n=22) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
44% (n=25) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical Remission 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 37.8% (n=90) vs 20.8% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=87) vs 20.8% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 50 further endpoints in the CSV export.

infliximab

Clinical Remission 60% (n=21) @ 2wk
responder rate · % of participants
No placebo or comparator arm
Weeks 2
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 80% (n=21) @ 6wk
responder rate · % of participants
No placebo or comparator arm
Weeks 6
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 80% (n=21) @ 8wk
responder rate · % of participants
No placebo or comparator arm
Weeks 8
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 77.8% (n=21) @ 10wk
responder rate · % of participants
No placebo or comparator arm
Weeks 10
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 87.5% (n=21) @ 14wk
responder rate · % of participants
No placebo or comparator arm
Weeks 14
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 87.5% (n=21) @ 18wk
responder rate · % of participants
No placebo or comparator arm
Weeks 18
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 64.3% (n=21) @ 22wk
responder rate · % of participants
No placebo or comparator arm
Weeks 22
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 85.7% (n=21) @ 26wk
responder rate · % of participants
No placebo or comparator arm
Weeks 26
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 64.3% (n=21) @ 30wk
responder rate · % of participants
No placebo or comparator arm
Weeks 30
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 42.9% (n=21) @ 30wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01585155 · Phase 3 · monotherapy
CAI 4 score @ 2wk
absolute change · score
No placebo or comparator arm
Weeks 2
NCT01585155 · Phase 3 · monotherapy
CAI 3.5 score @ 6wk
absolute change · score
No placebo or comparator arm
Weeks 6
NCT01585155 · Phase 3 · monotherapy

+ 30 further endpoints in the CSV export.

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody (fully human IgG1)
Partial signal

NCT00195676 · Phase 3 · completed

Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.

Next expected readout: April 2028 · NCT07529925 (registry estimate)

Reported efficacy

Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)

Result source: NCT00195676

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00106847 · Phase 3 · completed

This randomized, double-blind trial enrolled 683 patients and measured the proportion achieving at least 75% skin clearance (PASI 75), a standard psoriasis efficacy measure, at week 10. Infliximab produced clearance rates of 70-75% depending on dose, compared with 2% on placebo, a highly statistically significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) (Week 10): PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001) (met)

Result source: NCT01177800

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabinfliximab
PASI 7577.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
81% vs 2.2%+78.8 vs placebowk 10 · n 84NCT01177800
PASI 9061.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
—Not posted · NCT00106847
PASI 10018.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
—Not posted · NCT00106847
sPGA 0/160.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
88.1% vs 6.7%+81.4 vs placebowk 10 · n 84NCT01177800
1 other result
  • 0.8% vs 0.4% wk 16 · n 653 · Phase 3 · secondary NCT00251641
DLQI, change-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
-8 vs -1.5−6.5 vs placebowk 10 · n 84NCT01177800

PASI 75

adalimumab
77.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
infliximab
81% vs 2.2%+78.8 vs placebowk 10 · n 84NCT01177800

PASI 90

adalimumab
61.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
infliximab
—Not posted · NCT00106847

PASI 100

adalimumab
18.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
infliximab
—Not posted · NCT00106847

sPGA 0/1

adalimumab
60.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
infliximab
88.1% vs 6.7%+81.4 vs placebowk 10 · n 84NCT01177800
1 other result
  • 0.8% vs 0.4% wk 16 · n 653 · Phase 3 · secondary NCT00251641

DLQI, change

adalimumab
-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
infliximab
-8 vs -1.5−6.5 vs placebowk 10 · n 84NCT01177800
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. adalimumab: 14 of 14 rows · infliximab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
infliximab
Rows use multiple source trials
DLQI
absolute value · score
Induction
2.4 vs 2.1 EU RPP score @ 16wka,b,c
NCT02581345 · Phase 3 · registry result, not featured evidence
4.5 vs 9.25 placebo score @ 14wka,b,c
NCT00629772 · Phase 3 · registry result, not featured evidence
DLQI
absolute change · score
Maintenance
-8 vs -1.9 placebo score @ 26wkEOWa,b
NCT02016482 · Phase 3 · registry result, not featured evidence
-10.3 vs -9.2 placebo score @ 26wka,b
NCT01177800 · Phase 3
DLQI
percent change · % of baseline
No placebo or comparator arm
-79.16% (n=49) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
-68% (n=31) @ 24wk*5 mg/kga,b
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 68 Percent reduction as posted
DLQI
absolute change · score
No placebo or comparator arm
-8 score @ 52wka,b,d
NCT02533375 · Phase 3 · registry result, not featured evidence
12.7 score @ 12wk5 mg/kga,b,d
NCT00686686 · Phase 3 · registry result, not featured evidence
PASI 100
responder rate · % of participants
No placebo or comparator arm
64% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
40% (n=35) @ 24wk5 mg/kga,b
NCT00686595 · Phase 4 · registry result, not featured evidence
PASI 50
responder rate · % of participants
No placebo or comparator arm
96% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
40% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
89.9% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 80 Participants as posted
94.8% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 55 Participants as posted
89% (n=35) @ 24wk5 mg/kga,b
NCT00686595 · Phase 4 · registry result, not featured evidence
PASI 75
responder rate · % of participants
No placebo or comparator arm
82% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
4 other source trials
40% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
87.7% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
77.5% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted
86.2% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted
74% (n=35) @ 24wk5 mg/kga,b
NCT00686595 · Phase 4 · registry result, not featured evidence
PASI 90
responder rate · % of participants
No placebo or comparator arm
76% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
10% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
56.2% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted
67.2% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 39 Participants as posted
54% (n=35) @ 24wk5 mg/kga,b
NCT00686595 · Phase 4 · registry result, not featured evidence
sPGA 0/1
responder rate · % of participants
Maintenance
24.5% (n=49) vs 8.7% (n=23) placebo @ 28wk*e,a,b,f
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 12 subjects as posted
0.73% (n=653) vs 0.28% (n=215) Methotrexate @ 26wke,a,b,f
NCT00251641 · Phase 3 · registry result, not featured evidence
sPGA 0/1
responder rate · % of participants
No placebo or comparator arm
46.3% (n=1256) @ 120wka,b,g
NCT00195676 · Phase 3
65.4% (n=211) @ 10wk*a,b,g
NCT00527072 · Phase 3 · registry result, not featured evidence · converted to % from 138 participants as posted
Dropout rate
41.3%h
NCT00195676 · Phase 3
show 35 more results
6.7%
NCT00932113 · Phase 4 · registry result, not featured evidence
3%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
4.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
16.3%
NCT00735787 · Phase 4 · registry result, not featured evidence
9.4%
NCT05637515 · Phase 3 · registry result, not featured evidence
50%
NCT02533375 · Phase 3 · registry result, not featured evidence
5.2%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
13.8%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
21.1%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
33.3%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
1.5%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
11%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
17.2%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
2%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
2.9%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
7.7%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
7.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
11.8%40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
22.4%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
24.7%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
11.1%
NCT01320293 · Phase na · registry result, not featured evidence
11.9%h
NCT01177800 · Phase 3
show 17 more results
18.4%5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Over
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Plaq
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Pust
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Pl
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Ps
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Overall
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Plaque P
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Psoriati
NCT01680159 · Phase 3 · registry result, not featured evidence
16.7%
NCT00527072 · Phase 3 · registry result, not featured evidence
0%
NCT00629772 · Phase 3 · registry result, not featured evidence
18.9%5 mg/kg
NCT00687401 · Phase 3 · registry result, not featured evidence
26.1%5 mg/kg
NCT00686686 · Phase 3 · registry result, not featured evidence
17.2%
NCT00251641 · Phase 3 · registry result, not featured evidence
13.6%5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
5.6%h
NCT00195676 · Phase 3
show 35 more results
—
NCT00932113 · Phase 4 · registry result, not featured evidence
—
NCT01553058 · Phase 4 · registry result, not featured evidence
—
NCT01644396 · Phase 4 · registry result, not featured evidence
—
NCT01265823 · Phase 4 · registry result, not featured evidence
—
NCT00735787 · Phase 4 · registry result, not featured evidence
—
NCT05637515 · Phase 3 · registry result, not featured evidence
20%
NCT02533375 · Phase 3 · registry result, not featured evidence
1%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
4.6%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
2.6%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0.6%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
6.9%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.9%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
1.6%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
—80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
10.7%h
NCT01177800 · Phase 3
show 17 more results
7.9%5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Over
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Plaq
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Pust
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Pl
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Ps
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Overall
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Plaque P
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Psoriati
NCT01680159 · Phase 3 · registry result, not featured evidence
6%
NCT00527072 · Phase 3 · registry result, not featured evidence
—
NCT00629772 · Phase 3 · registry result, not featured evidence
3.8%5 mg/kg
NCT00687401 · Phase 3 · registry result, not featured evidence
8.7%5 mg/kg
NCT00686686 · Phase 3 · registry result, not featured evidence
12.3%
NCT00251641 · Phase 3 · registry result, not featured evidence
—5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence
Serious AEs
12.9%h
NCT00195676 · Phase 3
show 35 more results
0%
NCT00932113 · Phase 4 · registry result, not featured evidence
6.1%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
0.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
4.1%
NCT00735787 · Phase 4 · registry result, not featured evidence
1.7%
NCT05637515 · Phase 3 · registry result, not featured evidence
30%
NCT02533375 · Phase 3 · registry result, not featured evidence
—Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
1.4%Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
3.7%Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
7.3%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
3.2%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
5.7%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
7.7%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
1.2%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
3.4%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.4%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
4.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
19%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
21.3%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
4.8%h
NCT01177800 · Phase 3
show 17 more results
18.4%5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
9.8%TA-650(Dose Escalation Period)Over
NCT01680159 · Phase 3 · registry result, not featured evidence
12.9%TA-650(Dose Escalation Period)Plaq
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
14.3%TA-650(Dose Escalation Period)Pust
NCT01680159 · Phase 3 · registry result, not featured evidence
11.1%TA-650(Entire Evaluation Period)Pl
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Entire Evaluation Period)Ps
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Normal Dose Period)Overall
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Normal Dose Period)Plaque P
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Normal Dose Period)Psoriati
NCT01680159 · Phase 3 · registry result, not featured evidence
3.7%
NCT00527072 · Phase 3 · registry result, not featured evidence
16.7%
NCT00629772 · Phase 3 · registry result, not featured evidence
1.3%5 mg/kg
NCT00687401 · Phase 3 · registry result, not featured evidence
17.4%5 mg/kg
NCT00686686 · Phase 3 · registry result, not featured evidence
6.8%
NCT00251641 · Phase 3 · registry result, not featured evidence
0%5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
h
nasopharyngitis 26.6%
upper respiratory tract infection 20.3%
headache 11.2%
NCT00195676 · Phase 3
show 29 more results
upper respiratory tract infection 40%
dizziness 13.3%
flu-like symptoms 13.3%
NCT00932113 · Phase 4 · registry result, not featured evidence
upper respiratory infection 9.1% (placebo 12.9%)
joint range of motion decrease 6.1% (placebo 0%)
headache 3% (placebo 6.5%)
NCT01553058 · Phase 4 · registry result, not featured evidence
latent tuberculosis 8%
rhinitis 6%
alanine aminotransferase increased 2%
NCT01644396 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 11.3%
hyperglycemia 10.7%
arthralgia 6.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.5% (placebo 13%)
headache 14.3% (placebo 4.3%)
cough 8.2% (placebo 4.3%)
NCT00735787 · Phase 4 · registry result, not featured evidence
headache 2.2%
nasopharyngitis 2.2%
upper respiratory tract infection 2.2%
NCT05637515 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30%
pruritus 30%
hypoalbuminaemia 20%
NCT02533375 · Phase 3 · registry result, not featured evidence
injection site reaction 23.9%
nasopharyngitis 6.7%
headache 3.2%
NCT02581345 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
psoriasis 10.3%
injection site reaction 10%
NCT02581345 · Phase 3 · registry result, not featured evidence
EOW
upper respiratory tract infection 8.3% (placebo 8.3%)
headache 5.5% (placebo 0%)
nasopharyngitis 5.5% (placebo 9.3%)
NCT02016482 · Phase 3 · registry result, not featured evidence
EOW
nasopharyngitis 12.8% (placebo 9.3%)
upper respiratory tract infection 4.3% (placebo 8.3%)
depression 3.2% (placebo 0.9%)
NCT02016482 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 21.1%
headache 15.8%
dry skin 7.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 18.5%
back pain 11.1%
headache 11.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 28.7%
headache 25.3%
upper respiratory tract infection 14.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 25.6%
headache 17.9%
cough 10.3%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
cough 18.2%
decreased appetite 9.1%
gastroenteritis 9.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 23.1%
agitation 7.7%
cough 7.7%
NCT01251614 · Phase 3 · registry result, not featured evidence
Eow
upper respiratory tract infection 10.1% (placebo 6.9%)
oropharyngeal pain 4.1% (placebo 1.1%)
nasopharyngitis 3.8% (placebo 5.7%)
NCT01646073 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
cough 3.7%
headache 3.7%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.2%
injection site erythema 7.3%
nasopharyngitis 7.3%
NCT00566722 · Phase 3 · registry result, not featured evidence
fatigue 6.9%
pharyngitis 6.9%
abdominal pain 3.4%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18%
back pain 8%
common cold 8%
NCT00927069 · Phase 3 · registry result, not featured evidence
headache 11.4%
common cold 5.7%
upper respiratory tract infection 5.7%
NCT00927069 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.7%
headache 5.2%
psoriasis 5.2%
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
headache 6%
pruritus 5.8%
NCT00574249 · Phase 3 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.8%
upper respiratory tract infection 10.8%
headache 4.9%
NCT00513370 · Phase 3 · registry result, not featured evidence
80 mg every other week
nasopharyngitis 77.6%
blood triglycerides increased 29.3%
blood creatine phosphokinase increased 25.9%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 75.3%
blood triglycerides increased 24.7%
alanine aminotransferase increased 23.6%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 22.2%
elbow strain 5.6%
heartburn 5.6%
NCT01320293 · Phase na · registry result, not featured evidence
h
upper respiratory tract infection 14.3% (placebo 11.1%)
antinuclear antibody positive 11.9% (placebo 6.7%)
asthenia 11.9% (placebo 11.1%)
NCT01177800 · Phase 3
show 17 more results
5 mg/kg
pruritus 10.5%
rhinitis 7.9%
blood triglycerides increased 5.3%
NCT00686595 · Phase 4 · registry result, not featured evidence
double stranded dna antibody positive 49%
nasopharyngitis 27.5%
headache 7.8%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 58.1%
nasopharyngitis 22.6%
dyspnoea 9.7%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 25%
alanine aminotransferase increased 12.5%
arthralgia 12.5%
NCT01680159 · Phase 3 · registry result, not featured evidence
nasopharyngitis 60%
double stranded dna antibody positive 40%
alanine aminotransferase increased 20%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 42.9%
nasopharyngitis 42.9%
chapped lips 14.3%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 69.4%
nasopharyngitis 22.2%
dyspnoea 8.3%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 60%
alanine aminotransferase increased 10%
arthralgia 10%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 34.8%
nasopharyngitis 8.7%
psoriasis 4.3%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 33.3%
nasopharyngitis 11.1%
aspartate aminotransferase increased 2.8%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 40%
erythema 10%
feeling hot 10%
NCT01680159 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.8%
arthralgia 8.8%
headache 6.5%
NCT00527072 · Phase 3 · registry result, not featured evidence
common cold 25% (placebo 25%)
fatigue 16.7% (placebo 8.3%)
joint pain in hand 16.7% (placebo 0%)
NCT00629772 · Phase 3 · registry result, not featured evidence
5 mg/kg
pyrexia 5.7%
arthralgia 5%
NCT00687401 · Phase 3 · registry result, not featured evidence
5 mg/kg
hepatic enzyme increased 13%
asthenia 8.7%
folliculitis 8.7%
NCT00686686 · Phase 3 · registry result, not featured evidence
nasopharyngitis 18.3%
infusion related reaction 10.8%
headache 10.2%
NCT00251641 · Phase 3 · registry result, not featured evidence
5 mg/kg
pyrexia 18.2%
cough 13.6%
oropharyngeal pain 13.6%
NCT00687362 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 16 weeks versus 14 weeks.
  4. dAssessment timepoints differ: 52 weeks versus 12 weeks.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fAssessment timepoints differ: 28 weeks versus 26 weeks.
  7. gAssessment timepoints differ: 120 weeks versus 10 weeks.
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

BSA Involvement 5.9% (n=15) vs 10.7% (n=15) Methotrexate (MTX) @ 16wk
absolute value · percentage points
NCT00932113 · Phase 4 · registry result, not featured evidence
Target Lesion TOTAL 1.2 vs 3.4 Methotrexate (MTX) score @ 16wk
absolute change · score
NCT00932113 · Phase 4 · registry result, not featured evidence
Aortic Vascular Inflammation TBR -0.067 vs -0.052 placebo ratio @ 12wk
absolute change · ratio
NCT01553058 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL 1.48 vs 5 placebo mg/dL @ 12wk
absolute change · mg/dL
NCT01553058 · Phase 4 · registry result, not featured evidence
PASI 75 46.9% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PASI75
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 15 Participants as posted
PGA 0-1 43.8% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PGA Clear/Almost Clear
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
EQ-5D 0.07 vs 0 placebo score @ 12wk
absolute change · score
NCT01553058 · Phase 4 · registry result, not featured evidence
PGA =0 0% (n=50) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 11 more results
0% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
6% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
20% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
60% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
70% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
39.3% (n=333) @ 16wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
42.9% (n=333) @ 19wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
45.6% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
36.6% (n=41) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
20.7% (n=29) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
12.2% (n=82) @ 16wk*
NCT00566722 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted
PGA Improvement 40% (n=50) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 5 more results
74% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
98% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
98% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
100% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
96% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
PASI -20.42% (n=50) @ 2wk
percent change · % of baseline
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 15 more results
-45.75% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-69.28% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-81.74% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-89.42% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-91.18% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
-44.2% (n=10) @ 2wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-59.7% (n=10) @ 4wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-43.9% (n=10) @ 8wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-45% (n=10) @ 12wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-55.5% (n=10) @ 16wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-43.6% (n=10) @ 24wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-79% (n=10) @ 36wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-33.7% (n=10) @ 52wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-91.07% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
77.8% (n=18) @ 4wk*
NCT01872546 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
NAPSI -68.06% (n=22) @ 24wk
percent change · % of baseline
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 2 more results
-40% (n=213) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-37.5% (n=212) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
DLQI Less Than or Equal 5 65% (n=150) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01265823 · Phase 4 · registry result, not featured evidence
show 1 more result
86% (n=150) @ 16wk
NCT01265823 · Phase 4 · registry result, not featured evidence

+ 170 further endpoints in the CSV export.

infliximab

SAPASI -89% (n=31) @ 18wk5 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 89 Percent reduction as posted
show 1 more result
-82% (n=33) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 82 Percent reduction as posted
BSA -82% (n=32) @ 18wk5 mg/kg
absolute change · percentage points
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 82 Percent reduction as posted
show 1 more result
-72% (n=35) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 72 Percent reduction as posted
Pruritus VAS -81% (n=30) @ 18wk5 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 81 Percent reduction as posted
show 1 more result
-72% (n=33) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 72 Percent reduction as posted
PPPASI-75 33.3% (n=12) vs 8.3% (n=12) placebo @ 14wk
responder rate · % of participants
NCT00629772 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
Physician Global Assessment 2 vs 3.33 placebo score @ 14wk
absolute value · score
NCT00629772 · Phase 3 · registry result, not featured evidence
PPPASI 71.81% (n=12) @ 26wk
percent change · % of baseline
No placebo or comparator arm
NCT00629772 · Phase 3 · registry result, not featured evidence
Physician Global Assessment 47.92% (n=12) @ 26wk
percent change · % of baseline
No placebo or comparator arm
NCT00629772 · Phase 3 · registry result, not featured evidence
PPPASI-75 23.5% (n=17) @ 8wk5 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00686686 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted
PASI 75 0.78 vs 0.42 Methotrexate count @ 16wk
responder rate · count
NCT00251641 · Phase 3 · registry result, not featured evidence
show 1 more result
0.77 vs 0.31 Methotrexate count @ 26wk
NCT00251641 · Phase 3 · registry result, not featured evidence

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Reliable signal

NCT00195702 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).

Next expected readout: December 2027 · NCT06440629 (registry estimate)

Reported efficacy

Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)

Result source: NCT00195702

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Rheumatoid Arthritismonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00269867 · Phase 3 · completed

This randomised, double-blind, placebo-controlled trial in 428 patients with rheumatoid arthritis (ATTRACT) reported ACR20 responses of 50-58% across the infliximab plus methotrexate regimens against 20% on placebo plus methotrexate at week 30 (P<0.001 for each regimen), on a validated measure of disease activity.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabinfliximab
ACR2063.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
56.6% vs 53%vs Remicade-USwk 22 · n 228NCT02990806
51 other results
  • 62.6% vs 56.5% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 61.9% vs 56.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 60.8% vs 55.6% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 62.4% vs 55.6% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 56.8% vs 54.5% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 55.5% vs 48.8% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 48.8% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 55.9% vs 56.3% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 58.1% vs 50% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.4% vs 50% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 62.6% vs 61.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 61.7% vs 55.6% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 55.6% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 62.6% vs 62.3% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 62.1% vs 56.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 56.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 56.4% vs 51.1% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 52% vs 47.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 47.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 56.8% vs 52.2% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 56.4% vs 48.8% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 48.8% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 53.6% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 53.6% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 57.3% vs 54.4% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 60.9% vs 54.4% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 47.1% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 51.1% vs 48% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 51.3% vs 48% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 46.7% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 53.7% vs 50% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 50% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 31.3% vs 32.5% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 54.2% vs 50% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.9% vs 50% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 29.1% vs 31.8% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 56.4% vs 50.8% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 50.8% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 49.2% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 50.8% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 46.4% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 56.9% vs 46.4% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 54.2% vs 48.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 55.8% vs 48.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 52% vs 46.4% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 55.3% vs 46.4% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 47.2% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 56.7% vs 32.3% wk 14 · n 30 · Phase 2 · secondary NCT01313520
ACR5041.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
34.4% vs 32.3%vs Remicade USwk 26 · n 227NCT02990806
50 other results
  • 31% vs 32.3% wk 26 · n 446 · Phase 3 · secondary NCT02990806
  • 33% vs 31.9% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.9% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 27.8% vs 25.6% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 30% vs 28.6% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 30 · n 446 · Phase 3 · secondary NCT02990806
  • 27.8% vs 26.7% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 29.1% vs 28.2% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 28.4% vs 28.2% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.9% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.3% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.3% wk 34 · n 446 · Phase 3 · secondary NCT02990806
  • 31.7% vs 29.6% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.7% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.7% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 24.7% vs 21.3% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 31.3% vs 30.2% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 30.2% wk 38 · n 446 · Phase 3 · secondary NCT02990806
  • 23.3% vs 21.7% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 30.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 40.6% vs 36.7% wk 42 · n 446 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 37.1% vs 36.7% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 19.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 30.8% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.5% wk 46 · n 446 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.9% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 29.5% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 31.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 8.4% vs 8.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 37% vs 34.7% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 35.5% vs 34.7% wk 50 · n 446 · Phase 3 · secondary NCT02990806
  • 6.6% vs 6.7% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 34.8% vs 34.3% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 34.5% vs 34.3% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 36.6% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 28.6% wk 54 · n 446 · Phase 3 · secondary NCT02990806
  • 36.1% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.7% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 32.7% wk 58 · n 446 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.3% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 33.5% vs 32.3% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 30.8% vs 32.7% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 28.4% vs 32.7% wk 62 · n 446 · Phase 3 · secondary NCT02990806
  • 29.1% vs 32.7% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 27.9% vs 32.7% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 20% vs 0% wk 14 · n 30 · Phase 2 · secondary NCT01313520
ACR7047.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
16.3% vs 14.5%vs Remicade USwk 26 · n 227NCT02990806
49 other results
  • 13.2% vs 14.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 15.3% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 12.7% vs 15.3% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 10.6% vs 12.1% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 16.3% vs 15.3% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 15.3% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 11% vs 11.2% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 15.4% vs 14.1% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 11.7% vs 14.1% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 15% vs 11.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 18.1% vs 18.1% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 20.8% vs 18.1% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 14.5% vs 11% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 16.7% vs 16.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 19.3% vs 16.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 11% vs 7.8% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 17.6% vs 15.7% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 15.7% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 9.7% vs 7.4% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 16.3% vs 16.1% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.2% vs 16.1% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.5% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 18.5% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.3% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 17.3% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 6.6% vs 7.2% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 15% vs 18.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 5.7% vs 6.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 15.4% vs 16.9% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 16.9% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 22% vs 23% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 23% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.1% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 20.7% vs 22.6% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 22.6% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 18.1% vs 14.9% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 14.9% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 13.3% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 13.7% vs 13.3% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 18.9% vs 19.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 16.2% vs 19.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.1% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.1% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.5% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 18.5% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 18.1% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 15.2% vs 18.1% wk 62 · n 197 · Phase 3 · secondary NCT02990806
DAS28-CRP remission38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
—Not posted · NCT01217086
HAQ-DI, change-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
-0.4 vs -0.4vs Remicade USwk 26 · n 227NCT02990806
24 other results
  • -0.4 vs -0.4 wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.3 wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • -0.2 vs -0.3 wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 62 · n 197 · Phase 3 · secondary NCT02990806
Modified Sharp score, change0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
—Not posted · NCT01217086

ACR20

adalimumab
63.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
infliximab
56.6% vs 53%vs Remicade-USwk 22 · n 228NCT02990806
51 other results
  • 62.6% vs 56.5% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 61.9% vs 56.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 60.8% vs 55.6% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 62.4% vs 55.6% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 56.8% vs 54.5% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 55.5% vs 48.8% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 48.8% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 55.9% vs 56.3% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 58.1% vs 50% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.4% vs 50% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 62.6% vs 61.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 61.7% vs 55.6% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 55.6% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 62.6% vs 62.3% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 62.1% vs 56.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 56.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 56.4% vs 51.1% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 52% vs 47.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 47.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 56.8% vs 52.2% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 56.4% vs 48.8% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 48.8% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 53.6% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 53.6% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 57.3% vs 54.4% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 60.9% vs 54.4% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 47.1% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 51.1% vs 48% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 51.3% vs 48% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 46.7% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 53.7% vs 50% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 50% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 31.3% vs 32.5% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 54.2% vs 50% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.9% vs 50% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 29.1% vs 31.8% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 56.4% vs 50.8% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 50.8% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 49.2% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 50.8% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 46.4% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 56.9% vs 46.4% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 54.2% vs 48.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 55.8% vs 48.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 52% vs 46.4% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 55.3% vs 46.4% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 47.2% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 56.7% vs 32.3% wk 14 · n 30 · Phase 2 · secondary NCT01313520

ACR50

adalimumab
41.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
infliximab
34.4% vs 32.3%vs Remicade USwk 26 · n 227NCT02990806
50 other results
  • 31% vs 32.3% wk 26 · n 446 · Phase 3 · secondary NCT02990806
  • 33% vs 31.9% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.9% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 27.8% vs 25.6% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 30% vs 28.6% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 30 · n 446 · Phase 3 · secondary NCT02990806
  • 27.8% vs 26.7% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 29.1% vs 28.2% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 28.4% vs 28.2% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.9% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.3% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.3% wk 34 · n 446 · Phase 3 · secondary NCT02990806
  • 31.7% vs 29.6% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.7% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.7% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 24.7% vs 21.3% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 31.3% vs 30.2% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 30.2% wk 38 · n 446 · Phase 3 · secondary NCT02990806
  • 23.3% vs 21.7% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 30.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 40.6% vs 36.7% wk 42 · n 446 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 37.1% vs 36.7% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 19.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 30.8% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.5% wk 46 · n 446 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.9% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 29.5% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 31.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 8.4% vs 8.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 37% vs 34.7% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 35.5% vs 34.7% wk 50 · n 446 · Phase 3 · secondary NCT02990806
  • 6.6% vs 6.7% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 34.8% vs 34.3% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 34.5% vs 34.3% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 36.6% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 28.6% wk 54 · n 446 · Phase 3 · secondary NCT02990806
  • 36.1% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.7% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 32.7% wk 58 · n 446 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.3% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 33.5% vs 32.3% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 30.8% vs 32.7% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 28.4% vs 32.7% wk 62 · n 446 · Phase 3 · secondary NCT02990806
  • 29.1% vs 32.7% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 27.9% vs 32.7% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 20% vs 0% wk 14 · n 30 · Phase 2 · secondary NCT01313520

ACR70

adalimumab
47.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
infliximab
16.3% vs 14.5%vs Remicade USwk 26 · n 227NCT02990806
49 other results
  • 13.2% vs 14.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 15.3% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 12.7% vs 15.3% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 10.6% vs 12.1% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 16.3% vs 15.3% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 15.3% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 11% vs 11.2% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 15.4% vs 14.1% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 11.7% vs 14.1% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 15% vs 11.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 18.1% vs 18.1% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 20.8% vs 18.1% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 14.5% vs 11% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 16.7% vs 16.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 19.3% vs 16.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 11% vs 7.8% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 17.6% vs 15.7% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 15.7% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 9.7% vs 7.4% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 16.3% vs 16.1% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.2% vs 16.1% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.5% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 18.5% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.3% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 17.3% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 6.6% vs 7.2% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 15% vs 18.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 5.7% vs 6.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 15.4% vs 16.9% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 16.9% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 22% vs 23% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 23% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.1% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 20.7% vs 22.6% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 22.6% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 18.1% vs 14.9% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 14.9% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 13.3% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 13.7% vs 13.3% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 18.9% vs 19.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 16.2% vs 19.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.1% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.1% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.5% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 18.5% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 18.1% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 15.2% vs 18.1% wk 62 · n 197 · Phase 3 · secondary NCT02990806

DAS28-CRP remission

adalimumab
38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
infliximab
—Not posted · NCT01217086

HAQ-DI, change

adalimumab
-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
infliximab
-0.4 vs -0.4vs Remicade USwk 26 · n 227NCT02990806
24 other results
  • -0.4 vs -0.4 wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.3 wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • -0.2 vs -0.3 wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 62 · n 197 · Phase 3 · secondary NCT02990806

Modified Sharp score, change

adalimumab
0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
infliximab
—Not posted · NCT01217086
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety

Coverage. adalimumab: 17 of 17 rows · infliximab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
infliximab
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
79.6% (n=98) @ 26wk20 mg MTXa,b,c,d
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
76.8% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
74% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
67.3% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
35.5% (n=197) @ 26wk3 mg/kgb,c,d
NCT00714493 · Phase 4 · registry result, not featured evidence
2 other source trials
63.46% (n=104) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
76.15% (n=130) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
ACR50
responder rate · % of participants
No placebo or comparator arm
62.2% (n=98) @ 26wk20 mg MTXa,b,c
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
53.5% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
51% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
45.9% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
47.12% (n=104) @ 26wka,b,c
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
57.69% (n=130) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
ACR70
responder rate · % of participants
No placebo or comparator arm
45.9% (n=98) @ 26wk20 mg MTXa,b,c
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
41.4% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
34% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
24.5% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
29.81% (n=104) @ 26wka,b,c
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
29.23% (n=130) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
DAS28
absolute change · score
No placebo or comparator arm
-2.2 score @ 48wka,e,c,d,f
NCT01752855 · Phase 2 · registry result, not featured evidence
show 1 more dose
-2.4 score @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
-2.8 score @ 54wk10 mg/kga,e,c,d,f
NCT00691028 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2.57 score @ 54wk6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
-2.3 score @ 54wk3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
DAS28-CRP
absolute change · score
-2.3 vs -1.4 Standard of Care score @ 26wkg,c,d
NCT01162421 · Phase 4 · registry result, not featured evidence
-2.199 vs -2.317 Remicade US score @ 26wka,g,c,d
NCT02990806 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.192 vs -2.317 Remicade US score @ 26wk
NCT02990806 · Phase 3 · registry result, not featured evidence
DAS28-ESR
absolute change · score
-2.8 vs -1.8 placebo score @ 26wkc,d
NCT00870467 · Phase 3 · registry result, not featured evidence
-2.387 vs -2.533 Remicade US score @ 26wka,c,d
NCT02990806 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.375 vs -2.533 Remicade US score @ 26wk
NCT02990806 · Phase 3 · registry result, not featured evidence
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.82 score @ 26wk20 mg MTXa,b,c,d
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
-0.78 score @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
-0.71 score @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
-0.72 score @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
-0.223 score @ 26wk3 mg/kgb,c,d
NCT00714493 · Phase 4 · registry result, not featured evidence
2 other source trials
-0.59 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
-0.83 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Modified Sharp
absolute change · score
No placebo or comparator arm
1.6 score @ 52wka,c,d,h
NCT00870467 · Phase 3 · registry result, not featured evidence
show 1 more dose
9.6 score @ 52wk
NCT00870467 · Phase 3 · registry result, not featured evidence
0 score @ 54wk10 mg/kga,c,d,h
NCT00691028 · Phase 3 · registry result, not featured evidence
show 2 more doses
0.48 score @ 54wk6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
0 score @ 54wk3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
Morning Stiffness Duration
absolute change · minutes
No placebo or comparator arm
30 minutes @ 204wk40 mg every other weekb,c,d,i
NCT00235872 · Phase 3 · registry result, not featured evidence
-36.63 minutes @ 26wka,b,c,d,i
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-77.12 minutes @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Pain VAS
absolute change · score
No placebo or comparator arm
-7 score @ 264wk40 mg Eowj,c,d,k
NCT00235833 · Phase 2 · registry result, not featured evidence
-26.8 score @ 26wka,j,c,d,k
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-37.3 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Patient Global Assessment
absolute change · score
No placebo or comparator arm
-19.5 score @ 264wk40 mg Eowj,c,d,k
NCT00235833 · Phase 2 · registry result, not featured evidence
-28.3 score @ 26wka,j,c,d,k
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-39.3 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Physician Global Assessment
absolute change · score
No placebo or comparator arm
-35.5 score @ 264wk40 mg Eowj,c,d,k
NCT00235833 · Phase 2 · registry result, not featured evidence
-25.3 score @ 26wka,j,c,d,k
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-36.4 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
RAMRIS Synovitis
absolute change · score
-3.38 vs -3.88 placebo score @ 78wka,l,c,d,m
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-3.25 vs -3.88 placebo score @ 78wk
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
-2.3 vs 0.24 placebo score @ 14wkl,c,d,m
NCT01313520 · Phase 2 · registry result, not featured evidence
Dropout rate
23.2%40 mg every other weekn
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
20.8%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
24.8%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
32.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
10.3%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
12.3%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
9.2%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
6.1%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
7%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
15.3%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
39.4%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
26.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
36%
NCT00690573 · Phase 3 · registry result, not featured evidence
9.4%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
62.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
5%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
8.2%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
11.2%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
47.6%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
4.1%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
2%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
9.1%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
64%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—Infliximab + Methotrexate (Moderatn
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 13 more results
14.6%Infliximab + Methotrexate (Severe
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
—Stage 1, 2 and 3: NI-071 Group
NCT02990806 · Phase 3 · registry result, not featured evidence
—Stage 2 and Stage 3: Remicade US t
NCT02990806 · Phase 3 · registry result, not featured evidence
38%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
6.1%Open-label
NCT00691028 · Phase 3 · registry result, not featured evidence
0%
NCT01313520 · Phase 2 · registry result, not featured evidence
10%
NCT00948610 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weekn
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
—20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
1.3%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
3.9%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
4.5%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
3.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
0%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
9.9%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
11.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
—
NCT00690573 · Phase 3 · registry result, not featured evidence
—DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
22.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
3%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
4.4%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
11%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
0%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—Infliximab + Methotrexate (Moderatn
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 13 more results
5.4%Infliximab + Methotrexate (Severe
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
—Stage 1, 2 and 3: NI-071 Group
NCT02990806 · Phase 3 · registry result, not featured evidence
—Stage 2 and Stage 3: Remicade US t
NCT02990806 · Phase 3 · registry result, not featured evidence
17.4%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
4.9%Open-label
NCT00691028 · Phase 3 · registry result, not featured evidence
—
NCT01313520 · Phase 2 · registry result, not featured evidence
—
NCT00948610 · Phase na · registry result, not featured evidence
Serious AEs
13%40 mg every other weekn
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
16%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
7.4%maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
4.5%reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
2.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
7.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
1%Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
10.3%
NCT01162421 · Phase 4 · registry result, not featured evidence
7.1%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
3.9%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
11.4%ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
6.9%ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
7.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
23.7%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
20.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
24%
NCT00690573 · Phase 3 · registry result, not featured evidence
4.1%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
51.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
1%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
4.9%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.3%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
6.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
1.9%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
35.9%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
12.5%Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
2.3%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
4.5%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
0%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
0%Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
0%New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
40%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
1.9%Infliximab + Methotrexate (Moderatn
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 13 more results
1.5%Infliximab + Methotrexate (Severe
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
8.4%Stage 1, 2 and 3: NI-071 Group
NCT02990806 · Phase 3 · registry result, not featured evidence
6.6%Stage 2 and Stage 3: Remicade US t
NCT02990806 · Phase 3 · registry result, not featured evidence
13%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
8.7%10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
4.8%6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
7.1%3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
5.2%Open-label
NCT00691028 · Phase 3 · registry result, not featured evidence
0%
NCT01313520 · Phase 2 · registry result, not featured evidence
0%
NCT00948610 · Phase na · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weekn
injection site pain 17.9% (placebo 21.5%)
upper respiratory tract infection 16.9% (placebo 11%)
headache 11.6% (placebo 5%)
NCT00195702 · Phase 3
show 40 more results
20 mg weekly
injection site pain 17.5% (placebo 21.5%)
upper respiratory tract infection 16.5% (placebo 11%)
headache 13.2% (placebo 5%)
NCT00195702 · Phase 3
maximum tolerated dose
liver function test abnormal 8.8%
abdominal pain upper 2.9%
dry mouth 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
reduced dose
dry mouth 3%
alanine aminotransferase increased 1.5%
cough 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
40 mg Eow
cough 2.7% (placebo 5%)
nasopharyngitis 2.7% (placebo 20%)
urinary tract infection 1.4% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.3% (placebo 20%)
upper respiratory tract infection 7.7% (placebo 0%)
hepatic enzyme increased 5.1% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 20%)
arthralgia 5.9% (placebo 0%)
influenza 4.9% (placebo 10%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 25.6%
nasopharyngitis 20.5%
alanine aminotransferase increased 15.4%
NCT01162421 · Phase 4 · registry result, not featured evidence
high dose
nausea 10.3%
upper respiratory tract infection 7.7%
urinary tract infection 7.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
low dose
nausea 9.7%
fatigue 9.1%
upper respiratory tract infection 9.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
cough 6.7% (placebo 3.6%)
influenza 5.7% (placebo 2.7%)
nasopharyngitis 5.7% (placebo 3.6%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 11.2% (placebo 6.3%)
nasopharyngitis 8.9% (placebo 3.6%)
alanine aminotransferase increased 6.2% (placebo 2.7%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
injection site reaction 8.8%
headache 5.9%
nausea 5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
20 mg MTX
nasopharyngitis 11.2%
headache 9.2%
alopecia 8.2%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
10 mg MTX
nausea 13.1%
alopecia 6.1%
diarrhoea 6.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5 mg MTX
diarrhoea 6%
headache 6%
nasopharyngitis 6%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2.5 mg MTX
nausea 7.1%
arthralgia 6.1%
abdominal pain upper 4.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 22.6%
headache 21.5%
nausea 17.5%
NCT00195663 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.2%
headache 20.5%
upper respiratory tract infection 18.7%
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 56%
upper respiratory tract infection 56%
influenza 32%
NCT00690573 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.2% (placebo 16.6%)
hepatic function abnormal 8.2% (placebo 5.5%)
alanine aminotransferase increased 7.6% (placebo 3.7%)
NCT00870467 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 46.3%
rheumatoid arthritis 25.4%
sinusitis 24.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
40 mg/0.8 mL
nasopharyngitis 4%
respiratory disorder 4%
headache 3%
NCT01231321 · Phase 3 · registry result, not featured evidence
40 mg every other week
nausea 5.5% (placebo 5.3%)
headache 4.9% (placebo 5.3%)
nasopharyngitis 4.9% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 6.6% (placebo 5.3%)
upper respiratory tract infection 2.6% (placebo 7%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
upper respiratory tract infection 3.2% (placebo 7%)
nasopharyngitis 2.7% (placebo 5.3%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
nausea 6.2% (placebo 5.3%)
upper respiratory tract infection 5.2% (placebo 7%)
headache 4.7% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg or 80 mg every other week
nasopharyngitis 60.2%
adverse drug reaction 29.5%
antinuclear antibody positive 15.9%
NCT00603993 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 45%
adverse drug reaction 23.6%
dna antibody positive 16.2%
NCT00235872 · Phase 3 · registry result, not featured evidence
40 mg EOW
upper respiratory tract infection 14% (placebo 11.7%)
injection site pruritus 5.8% (placebo 0%)
nasopharyngitis 5.8% (placebo 6.7%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
80 mg EOW
upper respiratory tract infection 12.4% (placebo 11.7%)
nasopharyngitis 7.4% (placebo 6.7%)
injection site pruritus 4.1% (placebo 0%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
urinary tract infection 11.8%
abdominal discomfort 5.9%
arthralgia 5.9%
NCT03823391 · Phase 2 · registry result, not featured evidence
nasopharyngitis 12.5%
bronchitis 6.3%
drug hypersensitivity 6.3%
NCT03823391 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 8.2%
NCT02565810 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.9%
rheumatoid arthritis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.6%
cystitis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 10%
cystitis 8%
nausea 8%
NCT01712178 · Phase 2 · registry result, not featured evidence
pharyngitis 1.6%
rash erythematous 1.6%
protein urine present 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
protein urine present 1.6%
pharyngitis 0%
rash erythematous 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 60%
diarrhoea 24%
pruritus 20%
NCT00235833 · Phase 2 · registry result, not featured evidence
n
hepatic function disnormal 50%
upper respiratory infection 27.9%
fever 3.8%
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 9 more results
hepatic function disnormal 37.7%
upper respiratory infection 30%
hypolekocytosis 10.8%
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 12.3%
upper respiratory tract infection 10.6%
headache 7%
NCT02990806 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.7%
upper respiratory tract infection 10.2%
alanine aminotransferase increased 6.6%
NCT02990806 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.7%
pruritus 12%
urticaria 9.8%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
10 mg/kg
dna antibody positive 51.9%
nasopharyngitis 28.8%
antinuclear antibody positive 16.3%
NCT00691028 · Phase 3 · registry result, not featured evidence
6 mg/kg
dna antibody positive 55.8%
nasopharyngitis 27.9%
antinuclear antibody positive 14.4%
NCT00691028 · Phase 3 · registry result, not featured evidence
3 mg/kg
dna antibody positive 65.7%
nasopharyngitis 29.3%
antinuclear antibody positive 25.3%
NCT00691028 · Phase 3 · registry result, not featured evidence
nasopharyngitis 17.1%
alanine aminotransferase increased 10.1%
aspartate aminotransferase increased 6.1%
NCT00691028 · Phase 3 · registry result, not featured evidence
joint swelling 13.3% (placebo 19.4%)
headache 6.7% (placebo 0%)
palpitations 6.7% (placebo 0%)
NCT01313520 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fAssessment timepoints differ: 48 weeks versus 54 weeks.
  7. gTrial phases differ: Phase 4 versus Phase 3.
  8. hAssessment timepoints differ: 52 weeks versus 54 weeks.
  9. iAssessment timepoints differ: 204 weeks versus 26 weeks.
  10. jTrial phases differ: Phase 2 versus Phase 4.
  11. kAssessment timepoints differ: 264 weeks versus 26 weeks.
  12. lTrial phases differ: Phase 4 versus Phase 2.
  13. mAssessment timepoints differ: 78 weeks versus 14 weeks.
  14. nPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Modified Sharp 0.1 vs 2.7 placebo score @ 52wk40 mg every other week
absolute change · score
NCT00195702 · Phase 3
show 15 more results
0.3 vs 1.3 placebo score @ 24wk40 mg every other week
NCT00195702 · Phase 3
0.14 vs 4.83 placebo score @ 416wk40 mg every other week
NCT00195702 · Phase 3
0.72 vs 6.18 placebo score @ 520wk40 mg every other week
NCT00195702 · Phase 3
0.8 vs 2.7 placebo score @ 52wk20 mg weekly
NCT00195702 · Phase 3
0.6 vs 1.3 placebo score @ 24wk20 mg weekly
NCT00195702 · Phase 3
1.16 vs 4.83 placebo score @ 416wk20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
2.6 vs 6.18 placebo score @ 520wk20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
0.02 vs 0.88 Standard of Care score @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
0.16 vs 1.62 Standard of Care score @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
0.01 vs 2.24 Standard of Care score @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
3 vs 5.7 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence
1.3 vs 5.7 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
5.5 vs 10.4 Methotrexate score @ 104wk
NCT00195663 · Phase 3 · registry result, not featured evidence
1.9 vs 10.4 Methotrexate score @ 104wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
1.5 vs 2.4 placebo score @ 26wk
NCT00870467 · Phase 3 · registry result, not featured evidence
Sustained 8.7% (n=207) vs 1.5% (n=200) placebo40 mg every other week
responder rate · % of participants
NCT00195702 · Phase 3 · converted to % from 18 Participants as posted
show 1 more result
9.4% (n=212) vs 1.5% (n=200) placebo*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 20 Participants as posted
Modified Sharp 0.09 vs 2.66 placebo score @ 52wk40 mg every other week
absolute change · score
Actual progression during study
NCT00195702 · Phase 3
show 1 more result
0.77 vs 2.66 placebo score @ 52wk20 mg weekly
Actual progression during study
NCT00195702 · Phase 3
SDAI Remission 29.6% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
28.3% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
22% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
11.2% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
37.9% (n=66) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
39.7% (n=58) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
HAQ-DI Less Than 0.5 58.8% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
mTSS no Progression 66.2% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
Time to Flare NA vs NA placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence
Disease Flare 36.3% (n=102) vs 45% (n=20) placebo
responder rate · % of participants
NCT02198651 · Phase 4 · registry result, not featured evidence
show 1 more result
15.4% (n=39) vs 8.6% (n=35) Standard of Care @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
Clinical Remission 10% (n=30) vs 12.5% (n=8) placebo @ 0wk
responder rate · % of participants
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 3 more results
46.7% (n=30) vs 12.5% (n=8) placebo @ 4wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
56.7% (n=30) vs 37.5% (n=8) placebo @ 10wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
43.3% (n=30) vs 50% (n=8) placebo @ 16wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
Time to Clinical Remission 1.41 vs 4.15 placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to months from 6.1 weeks as posted
DAS28-ESR LDAS 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wk
responder rate · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
20.5% (n=454) vs 18.1% (n=454) ADA+MTX @ 6wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
30.4% (n=454) vs 29.7% (n=454) ADA+MTX @ 12wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
All-Cause Discontinuation 0% (n=353) vs 0.0028% (n=361) ADA+MTX @ 13wk
event count · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 7 more results
0.0198% (n=353) vs 0.0332% (n=361) ADA+MTX @ 26wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.0453% (n=353) vs 0.0609% (n=361) ADA+MTX @ 39wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.0963% (n=353) vs 0.0886% (n=361) ADA+MTX @ 52wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.1643% (n=353) vs 0.1607% (n=361) ADA+MTX @ 65wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2181% (n=353) vs 0.1967% (n=361) ADA+MTX @ 78wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2408% (n=353) vs 0.2105% (n=361) ADA+MTX @ 91wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination

+ 219 further endpoints in the CSV export.

infliximab

EULAR Good, Moderate 49.7% (n=197) @ 10wk3 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00714493 · Phase 4 · registry result, not featured evidence
show 1 more result
51.8% (n=197) @ 26wk3 mg/kg
NCT00714493 · Phase 4 · registry result, not featured evidence
Swollen Joint Count -2.6 Swollen joints @ 26wk
absolute change · Swollen joints
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-7.7 Swollen joints @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
TJC -4 Tender joints @ 26wk
absolute change · Tender joints
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-10.6 Tender joints @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
CRP Change -0.54 mg @ 26wk
absolute change · mg
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-1.22 mg @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
ESR Change MM h -2.19 mm @ 26wk
absolute change · mm
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-16.53 mm @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
RAPID3 -2.99 vs -3.79 Remicade-US score @ 2wk
absolute change · score
NCT02990806 · Phase 3 · registry result, not featured evidence
show 24 more results
-4.15 vs -5.05 Remicade-US score @ 6wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.04 vs -4.91 Remicade-US score @ 14wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.99 vs -5.73 Remicade-US score @ 18wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-4.71 vs -5.41 Remicade-US score @ 22wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.81 vs -6.34 Remicade US score @ 26wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.64 vs -6.34 Remicade US score @ 26wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.43 vs -6.41 Remicade US score @ 30wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.26 vs -6.41 Remicade US score @ 30wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.24 vs -7.39 Remicade US score @ 34wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.22 vs -7.39 Remicade US score @ 34wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.91 vs -6.59 Remicade US score @ 38wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.86 vs -6.59 Remicade US score @ 38wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.69 vs -7.4 Remicade US score @ 42wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.49 vs -7.4 Remicade US score @ 42wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.34 vs -7.11 Remicade US score @ 46wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.79 vs -7.11 Remicade US score @ 46wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.85 vs -7.94 Remicade US score @ 50wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.48 vs -7.94 Remicade US score @ 50wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.63 vs -7.11 Remicade US score @ 54wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.38 vs -7.11 Remicade US score @ 54wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.84 vs -7.83 Remicade US score @ 58wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-6.41 vs -7.83 Remicade US score @ 58wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.35 vs -6.28 Remicade US score @ 62wk
NCT02990806 · Phase 3 · registry result, not featured evidence
-5.74 vs -6.28 Remicade US score @ 62wk
NCT02990806 · Phase 3 · registry result, not featured evidence
SF-36 Total 79.9 vs 77.59 Remicade-US score @ 14wk
absolute change · score
NCT02990806 · Phase 3 · registry result, not featured evidence
show 5 more results
90.02 vs 82.94 Remicade-US score @ 22wk
NCT02990806 · Phase 3 · registry result, not featured evidence
95.1 vs 96.93 Remicade US score @ 38wk
NCT02990806 · Phase 3 · registry result, not featured evidence
87.61 vs 96.93 Remicade US score @ 38wk
NCT02990806 · Phase 3 · registry result, not featured evidence
81.56 vs 95.24 Remicade US score @ 62wk
NCT02990806 · Phase 3 · registry result, not featured evidence
87.51 vs 95.24 Remicade US score @ 62wk
NCT02990806 · Phase 3 · registry result, not featured evidence
ACR-N 58.3% (n=104) @ 54wk10 mg/kg
absolute value · percentage points
No placebo or comparator arm
NCT00691028 · Phase 3 · registry result, not featured evidence
show 2 more results
53.8% (n=104) @ 54wk6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
51.3% (n=99) @ 54wk3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
Tender Joint 4.8 count @ 54wk10 mg/kg
event count · count
No placebo or comparator arm
Tender joint count, week54
NCT00691028 · Phase 3 · registry result, not featured evidence
show 2 more results
4.8 count @ 54wk6 mg/kg
Tender joint count, week54
NCT00691028 · Phase 3 · registry result, not featured evidence
6.3 count @ 54wk3 mg/kg
Tender joint count, week54
NCT00691028 · Phase 3 · registry result, not featured evidence
Swollen Joint 3 count @ 54wk10 mg/kg
event count · count
No placebo or comparator arm
Swollen joint count, week 54
NCT00691028 · Phase 3 · registry result, not featured evidence
show 2 more results
3.3 count @ 54wk6 mg/kg
Swollen joint count, week 54
NCT00691028 · Phase 3 · registry result, not featured evidence
3.6 count @ 54wk3 mg/kg
Swollen joint count, week 54
NCT00691028 · Phase 3 · registry result, not featured evidence
RAMRIS Osteitis -3.1 vs 0.48 placebo score @ 14wk
absolute change · score
NCT01313520 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · infliximab's landscape